PD Dr. Benjamin Heidrich participates in RESIST research project B11.
| My Research Interest in RESIST |
Our research focus in RESIST is the susceptibility to cholangitis and individual treatment approaches in primary sclerosing cholangitis (PSC) before and after liver transplantation (LTX) (SusTreat-PSC). The biliary tract was considered to be a sterile niche. However, we and others could show that even in healthy individuals there is an existing biliary microbiota. Patients with PSC are at high risk to develop bacterial cholangitis often chronic recurrent cholangitis leading to chronic liver failure and the need of liver transplantation.
Within RESIST we are interest to define the bacteria and their specific mechanisms being involved in the development of bacterial cholangitis. With the knowledge we plan to improve the recommendations regarding antibiotic therapies, define new treatment approaches for targeted therapies and implement screening methods for patients at risk of bacterial cholangitis.
Prof. Heidrich about his scientific work
PD Dr. Benjamin Heidrich – Curriculum Vitae
Current Position
Undergraduate and Postgraduate Training
Academic and Research Posts
Other Scientific Roles
Awards and Prizes
10 Selected Publications
Wellhöner F, Döscher N, Tergast TL, Vital M, Plumeier I, Kahl S, Potthoff A, Manns MP, Maasoumy B, Wedemeyer H, Cornberg M, Pieper DH, and Heidrich B. The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients. Scandinavian Journal of Gastroenterology July 2019 (accepted)
Schlegel T, Schallert K, Vilchez-Vargas R, Benndorf D, Püttker S, Sydor S, Schulz C, Bechmann L, Canbay A, Heidrich B, Reichl U, Link A, Heyer R. Metaproteomics of fecal samples of Crohn’s Disease and Ulcerative Colitis. J Proteomics. 2019 Apr 19. pii: S1874-3919(19)30113-7.
Wedemeyer H*, Yurdaydin C*, Hardtke S, Caruntu FS, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Keskin O, Port K, Radu M, Celen MK, Idilman R, Weber K, Stift J, Wittkop U, Heidrich B, Mederacke I, von der Leyen H, Dienes HP, Cornberg M, Koch A, Manns MP, for the HIDIT-II study team. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. Lancet Infect Dis. 2019 Mar;19(3):275-286
Lutterkort GL, Wranke A, Hengst J, Yurdaydin C, Stift J, Bremer B, Hardtke S, Keskin O, Idilman R, Mann MP, Dienes HP, Falk C, Wedemeyer H, Heidrich B. Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy. J Viral Hepat. 2018 Nov;25(11):1384-1394.
Heidrich B, Vital M, Plumeier I, Döscher N, Kahl S, Kirschner J, Ziegert S, Philipp S, Lenzen H, Potthoff A, Manns MP, Wedemeyer H, and Pieper DH. Intestinal microbiota in patients with chronic hepatitis C with and without liver cirrhosis compared to healthy controls. Liver Int. 2018 Jan;38(1):50-58.
Rath S, Heidrich B, Pieper DH, Vital M. Uncovering the trimethylamine-producing bacteria of the human gut microbiota. Microbiome. 2017 May 15;5(1):54.
Wranke A, Calle Serrano B, Heidrich B, Kirschner J, Bremer B, Lehmann P, Hardtke S, Deterding K, Port K, Westphal M, Manns MP, Cornberg M, Wedemeyer H. Antiviral treatment and liver-related complications in hepatitis delta. Hepatology. 2017 Feb;65(2):414-425.
Lutterkort GL, Wranke A, Yurdaydin C, Budde E, Westphal M, Lichtinghagen R, Stift J, Bremer B, Hardtke S, Keskin O, Idilman R, Koch A, Manns MP, Dienes HP, Wedemeyer H, Heidrich B. Non-Invasive Fibrosis Score for Hepatitis Delta. Liver Int. 2017 Feb;37(2):196-204.
Heidrich B, Steinmann E, Plumeier I, Kirschner J, Sollik L, Ziegert S, Engelmann M, Lehmann P, Manns MP, Pieper DH, and Wedemeyer H. Frequent detection of HCV RNA and HCVcoreAg in stool of patients with chronic hepatitis C. J Clin Virol. 2016 Jul;80:1-7.
Heidrich B, Yurdaydın C, Kabaçam G, Ratsch BA, Zachou K, Bremer B, Dalekos GN, Erhardt A, Tabak F, Yalcin K, Gürel S, Zeuzem S, Cornberg M, Bock CT, Manns MP, and Wedemeyer H for the HIDIT-1 Study group. Late HDV RNA relapse after peginterferon alfa-based therapy of chronic hepatitis delta. Hepatology. 2014 Jul;60(1):87-97.
